Floyd Taub, M.D. - Publications on Beta-alethine (Beta LT™)

Taub, F. Beta-alethine (Beta LT™): A Low Molecular Weight Cytokine Inducer with Anti-Cancer Properties and Low Toxicity in Mice and Man? Review of Data to Date. Poster presented at Cancer Immunosurveillance 1999 - Cancer Research Institute, New York, New York 1999.
Taub F, Mayerson S, McQuillan A, Caplan S, Shustik C, Miller W. Phase I/II Evaluation of Beta LT™ as an antilymphoma agent and enhancer of DTH in lymphoma patients. Poster presented at The International Conference on Molecular Targets and Cancer Therapeutics, Washington, D.C. 1999.
Miller WH, Caplan S, Shustik C, McQuillan A, Sicilia F, Mayerson S, Taub F. Beta-alethine Immunomodulation in Follicular B Cell Lymphoma and Multiple Myeloma: Initial Phase I/II Results. Submitted. Blood Supplement (Part II), November 15, 1999.
W.H. Miller, Jr., S. Caplan, C., Shustik, A. McQuillan, F. Sicilia, S. Mayerson and F. Taub. Beta-alethine: TNF alpha, Antitumor Effects and Delayed Type Hypersensitivity in Follicular B-Cell Lymphoma. Oral presentation at the ISH 2000 (28th International Congress) Toronto, Ontario, August 2000.
F. Taub. Review of Beta LT immunomodulation in lab studies and patients with follicular B cell lymphoma: Initial phase I/II results. Presented at the Comprehensive Cancer Care 2000, Arlington, VA, June 2000.
F. Taub, K. Manos, S. Mayerson. A review of animal models and human clinical trial data supportive of beta-alethine (BT) immune therapy for minimal residual disease (MRD). Presented at the 15th Annual Scientific Meeting of the Society for Biological Therapy, Seattle, WA October 2000.
W.H. Miller, Jr., S. Caplan, C., Shustik, A. McQuillan, F. Sicilia, S. Mayerson and F. Taub. T cells exhibit increased TNF alpha and delayed type hypersensitivity responses are restored in patients with B cell malignancies following administration of beta-alethine. Presented at the American Association for Cancer Research, 11th NCI-EORTC-AACR Symposium Amsterdam, The Netherlands, November 2000.
C.H. Pontzer and F. Taub. Reducing toxicity of recombinant biomolecules through engineering. Presented at the Cambridge Healthtech Institute Recombinant Therapeutics: Antibodies and Biomolecules Conference, Baltimore, MD, June 2001.